Pharma Supply Chains in the Crossfire - Takeaways - MDSpire

Pharma Supply Chains in the Crossfire

  • May 5, 2026

Share

  • 1

    The US Supreme Court ruled that the President cannot impose tariffs under the International Emergency Economic Powers Act, complicating compliance for pharma companies.

  • 2

    Pharmaceutical companies face rising costs and delays in clinical trials due to geopolitical tensions and existing tariffs, impacting their operational strategies.

  • 3

    Organizations must conduct granular audits to assess the impact of overturned tariffs and existing duties, while seeking exemptions to mitigate financial losses.

  • 4

    Companies are reevaluating their manufacturing locations and clinical trial plans due to policy volatility and uncertain cost forecasts.

  • 5

    The ongoing conflict in the Middle East is expected to increase costs and supply shortages across the pharmaceutical industry, affecting logistics and planning.

Original Source(s)

Pharma Supply Chains in the Crossfire

  • May 5, 2026

Related Content

FDA Cleared ≠ FDA Validated

Most AI medical devices reach the market without independent evidence of safety or effectiveness.

AI Outperforms MDs on Reasoning Tasks

Across six experiments—including a blinded, real-world ER evaluation—an OpenAI large language model outperformed physician baselines on multiple clinical reasoning tasks, though not on key safety endpoints such as cannot-miss diagnoses

Food Fight Brewing in Hospitals

New federal diet push collides with clinical realities, as doctors weigh patient needs against policy signals.